- Home
- ELVN vs AUTL Comparison
ELVN vs AUTL Comparison
Compare ELVN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- AUTL
- Stock Information
- Founded
- ELVN 2016
- AUTL 2014
- Country
- ELVN United States
- AUTL United Kingdom
- Employees
- ELVN N/A
- AUTL N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELVN Health Care
- AUTL Health Care
- Exchange
- ELVN Nasdaq
- AUTL Nasdaq
- Market Cap
- ELVN 1.3B
- AUTL 1.1B
- IPO Year
- ELVN 2020
- AUTL 2018
- Fundamental
- Price
- ELVN $25.91
- AUTL $2.93
- Analyst Decision
- ELVN Strong Buy
- AUTL Strong Buy
- Analyst Count
- ELVN 4
- AUTL 3
- Target Price
- ELVN $36.75
- AUTL $10.20
- AVG Volume (30 Days)
- ELVN 244.8K
- AUTL 2.6M
- Earning Date
- ELVN 11-13-2024
- AUTL 11-12-2024
- Dividend Yield
- ELVN N/A
- AUTL N/A
- EPS Growth
- ELVN N/A
- AUTL N/A
- EPS
- ELVN N/A
- AUTL N/A
- Revenue
- ELVN N/A
- AUTL $10,091,000.00
- Revenue This Year
- ELVN N/A
- AUTL $816.67
- Revenue Next Year
- ELVN N/A
- AUTL $374.47
- P/E Ratio
- ELVN N/A
- AUTL N/A
- Revenue Growth
- ELVN N/A
- AUTL 82.71
- 52 Week Low
- ELVN $9.80
- AUTL $2.69
- 52 Week High
- ELVN $30.03
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- ELVN 41.12
- AUTL 32.14
- Support Level
- ELVN $24.69
- AUTL $2.69
- Resistance Level
- ELVN $26.48
- AUTL $3.25
- Average True Range (ATR)
- ELVN 1.38
- AUTL 0.32
- MACD
- ELVN -0.32
- AUTL -0.07
- Stochastic Oscillator
- ELVN 28.35
- AUTL 7.67
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.